• Veteran executive with broad board-level experience at biotechnology firms in the US and Europe
• Provides significant operational, strategic, and deal-making knowledge as AstronauTx moves forward its novel pipeline aimed at enhancing sleep architecture to address neurodegenerative conditions

LONDON, Jan. 7, 2026 — AstronauTx Ltd (“AstronauTx”), a biotech firm creating treatments for Alzheimer’s Disease and other neurological disorders through the enhancement of sleep architecture, today declared the appointment of Adam Rosenberg as Chairman of its Board of Directors.

Adam is a seasoned biotech leader and board member with over twenty years of demonstrated success in building companies within the life sciences sector. He has co-founded and managed several prosperous biotech companies, supervising numerous high-value collaborations and acquisitions with major pharmaceutical corporations, and has held the position of Chairman or independent director on several boards of venture-backed and publicly traded companies.

Adam contributes deep knowledge from serving as both CEO and director for organizations focused on researching and developing therapies for central nervous system diseases. His CEO roles have included Aliada Therapeutics, Athenen Therapeutics, Link Medicine, Rodin Therapeutics, and Teleos Therapeutics, all concentrating on neuroscience. He was also the founding CEO of Sionna Therapeutics. Presently, he serves as CEO of RyCarma Therapeutics and Chairman of Seamless Therapeutics and VectorY Therapeutics.

Jane Rhodes, Chief Executive Officer of AstronauTx, stated: “Adam’s profound background in establishing successful neuroscience ventures and guiding key strategic deals will be extremely valuable as AstronauTx moves into its next growth stage. His guidance and stewardship arrive at a crucial moment while we advance our programs toward clinical trials and further solidify our role as innovators creating treatments at the crossroads of sleep science and neurodegenerative illness.”

“I also want to acknowledge Tim Edwards and express gratitude for his significant role in founding and developing AstronauTx in recent years, and extend best wishes for his future pursuits.”

Adam Rosenberg, newly appointed Chair of AstronauTx’s Board of Directors, remarked: “Understanding of the critical link between sleep quality, cognitive performance, and disease advancement is growing. AstronauTx’s strategy of targeting sleep as a therapeutic pathway for neurodegenerative disorders could revolutionize the treatment of Alzheimer’s and other neurological diseases. I am eager to collaborate with Jane and the team to support the Company’s ongoing development.”

About AstronauTx Ltd

AstronauTx’s methodology is based on a blend of clear, measurable biological goals—including EEG-derived sleep structure measurements and quantifiable gains in cognitive function and glymphatic system activity—and a data-driven plan incorporating sophisticated analytics. Through the analysis of extensive, high-quality EEG data, the firm seeks to accurately measure sleep structure and treatment effects. This facilitates the detection of nuanced patterns and biomarkers, leading to a deeper insight into how modulating slow wave sleep affects cognitive results and the course of disease.

Established by SV Health’s Dementia Discovery Fund, AstronauTx secured a £48 million ($61 million) Series A funding round in October 2023. The round was headed by the Novartis Venture Fund, with contributions from SV’s Dementia Discovery Fund, MPM BioImpact, Brandon Capital, EQT Life Sciences, and Bristol Myers Squibb.